Want to see NASC full AI Analyst Report?
Nascent Pharma Holdings (NASC) Income Statement
Nascent Pharma Holdings Income Statement
Last quarter (Q3 2024), Nascent Pharma Holdings's total revenue was $15.27K, a decrease of 96.36% from the same quarter last year. In Q3, Nascent Pharma Holdings's net income was $-3.26M. See Nascent Pharma Holdings’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Mar 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 2.16M | $ 6.69M | $ 4.60M | $ 1.71M | |
| $ -742.32K | $ 358.70K | $ 2.61M | $ 2.99M | $ 1.43M | |
| $ 4.02M | $ 7.85M | $ 16.78M | $ 13.26M | $ 8.97M | |
| Depreciation and Amortization | $ 343.61K | $ 1.40M | $ 1.43M | $ 542.35K | $ 783.30K |
| $ -7.65M | $ -5.82M | $ -12.59M | $ -9.52M | $ -7.16M | |
| $ -4.76M | $ -7.49M | $ -14.17M | $ -10.27M | $ -7.54M | |
| $ -5.02M | $ -2.24M | $ -755.24K | $ -1.90M | $ -1.34M | |
| $ -9.78M | $ -9.73M | $ -14.92M | $ -12.17M | $ -8.88M | |
| $ -10.20M | $ -9.74M | $ -14.92M | $ -12.17M | $ -8.88M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.17 | $ -0.77 | $ -4.18 | $ -9.06 | $ -37.68 |
| Diluted EPS | $ -0.17 | $ -0.77 | $ -4.18 | $ -9.06 | $ -37.68 |
| Weighted Average Shares Outstanding | 58.37M | 12.59M | 3.57M | 1.34M | 235.65K |
| Weighted Average Shares Outstanding (Diluted) | 58.37M | 12.59M | 3.57M | 1.34M | 235.65K |
Currency in USD
